Worth reading
66In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Announced details
Brincidofovir (BCV)Combination therapy with immune checkpoint inhibitors (ICIs)
Applicable field (uses covered by this announcement)
Treatment of EBV-associated gastric cancer (EBVaGC), including combination therapy with immune checkpoint inhibitors
Launch date30 May 2026 (presentation date)
Relationship between the counterparty and the company
SymBio Pharmaceuticals Limited4582
Relationship with the Company
The society at which SymBio Pharmaceuticals presented its research findings.
CounterpartyAmerican Society of Clinical Oncology (ASCO)
Founded in 1964, the international society for cancer treatment and research has more than 50,000 members from over 150 countries.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Source (materials cited by the company)
American Society of Clinical Oncology (ASCO 2026)
| Item | Details |
|---|---|
| Names of Products / Services Covered | Brincidofovir (BCV), Combination therapy with immune checkpoint inhibitors (ICIs) |
| Counterparty | American Society of Clinical Oncology (ASCO) |
| Counterparty overview | Founded in 1964, the international society for cancer treatment and research has more than 50,000 members from over 150 countries. |
| Relationship with the Company | The society at which SymBio Pharmaceuticals presented its research findings. |
| Launch date | 30 May 2026 (presentation date) |
| Applicable area | Treatment of EBV-associated gastric cancer (EBVaGC), including combination therapy with immune checkpoint inhibitors |
| Source | American Society of Clinical Oncology (ASCO 2026) |
Items this document does not state (11)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To apply the research findings to the future clinical development of BCV and maximize its business value.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.